March 14, 2023 02:54 PM EDTUpdated 04:06 PM

EU lays out pros and cons to onshoring more API production

Tyler Patchen

News Reporter

As the US embarks on a billion-dollar initiative to onshore active pharmaceutical ingredient (API) manufacturing, the European Union released a report earlier this month weighing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EU lays out pros and cons to onshoring more API production

Tyler Patchen

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

EU lays out pros and cons to on­shoring more API pro­duc­tion

Tyler Patchen

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Ex­clu­sive: To de­vel­op bet­ter cell ther­a­pies for sol­id tu­mors, a new start­up plans to test hun­dreds of them at once

With a $372M megaround, For­ma­tion Bio looks to in-li­cense 10+ drugs

EU lays out pros and cons to onshoring more API production

Why the Supreme Court's overrule of Chevron has major implications for the FDA

Scientists unveil new way to make large changes to genes, and no CRISPR is required

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Exclusive: To develop better cell therapies for solid tumors, a new startup plans to test hundreds of them at once

With a $372M megaround, Formation Bio looks to in-license 10+ drugs